Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

DAB2 (disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila))

Identity

Other namesDAB-2
DOC-2
DOC2
FLJ26626
HGNC (Hugo) DAB2
Location 5p13.1
Location_base_pair Starts at 39407537 and ends at 39461092 bp from pter ( according to hg18-Mar_2006)  [Mapping]
Local_order The complement factor 9 (C9) gene is located at the 3'-end of the DAB2 gene.
Note DAB2 was first identified as DOC-2, for differentially expressed in ovarian carcinoma, and subsequently as a protein whose phosphorylation is stimulated by CSF-1.

DNA/RNA

Description The DAB2 gene consists of 15 exons and 14 introns spanning in a region of 35 kb in size.
Transcription The putative DAB2 promoter was identified within a 420-bp sequence upstream of the exon1/intron1 junction. DAB2 is alternatively spliced to generate several transcripts and proteins. The transcript has been detected in spleen, thymus, prostate, testis, small intestine, and abundant in ovary.

Protein

Note DAB2 plays a pivotal role in the control of cellular homeostasis. The adaptor protein DAB2 is implicated in several receptor-mediated signaling pathways, endocytosis, cell adhesive function, hematopoietic cell differentiation, and angiogenesis.
 
  Schematic representation of DAB2 domains. DAB2 possess a highly conserved N-terminal phosphotyrosine-interacting/phosphotyrosine binding domain (PID/PTB), renamed the DAB homology domain, and a C-terminal proline-rich domain (PRD).
Description 770 amino acids, molecular weight 82.5 kDa. DAB2 contains an N-terminal PID/PTB domain (amino acid 42-180) and three C-terminal proline-rich domains (amino acid 619-627, 663-671, and 714-722). A potential actin-binding motif, KKEK is present in the N-terminal domain.
Expression Widely expressed. Cytoplasmic. DAB2 is expressed in many epithelial cell types and was suggested to have a role in epithelial organization. dab2 knock-out mice are embryonic lethal for defective visceral endoderm cell organization. In fact, in dab2 (-/-) mice, the epithelial cells of the early embryos (visceral endoderm) mix within the interior rather then align as a layer covering the inner cell mass. The role of Dab2 in mediating directional trafficking of endocytic proteins to establish apical polarity is suggested as a mechanism for surface positioning of endoderm cells.
Function The PID/PTB and PRD domains of DAB2 associate with several proteins, and these interactions have been shown to modulate protein trafficking, cytoskeleton organization, cell adhesion and migration, and cell signaling of various receptor protein-tyrosine kinases.

  • Cell cycle: DAB2 was identified as a protein phosphorylated in response to mitogenic stimulation by CSF-1. In cells, protein phosphorylation of DAB2 modulates its functional activity. Protein kinase C (PKC) and Cdc2 are the two known DAB2 kinases. The major PKC phosphorylation site has been mapped to Ser24 and it is essential for the inhibitory function of DAB2 in TPA-induced AP-1 gene transcription. DAB2 is differentially phosphorylated during the cell cycle by cdc2, and its phosphorylation promotes the association of DAB2 with Pin1, that regulates the rate of DAB2 dephosphorylation.

  • Vesicle traffic: DAB2 plays a role in linking specific extracellular receptors to the endocytic machinery. DAB2 associates with AP-2-positive clathrin-coated structures, together with endocytosed trans-membrane proteins such as low-density lipoprotein (LDL) receptors and integrins. DAB2 also binds to the actin-based myosin VI, mediating the attachment of cargos to motor proteins and regulating protein trafficking.

  • Signaling pathways:
    - TGFbeta - Dab2 associates with Smad2 and Smad3, by a direct interaction with the PID/PTB domain of Dab2, and with TGFbeta receptor I and TGFbeta receptor II. Thus Dab2 may be an essential component of the TGFbeta signaling pathway allowing the transmission of signals from the TGFbeta receptors to the Smad family of transcriptional activators.
    - WNT - Dab2 associates with Axin and stabilizes its expression by preventing Axin interaction with the LRP5 co-receptor. Thus the interaction of Axin with beta-catenin results stabilized with an increase in beta-catenin degradation and attenuation of Wnt signaling.
    - RAS/RAF/MAPK - In cell culture experiments, a Dab2 over-expression leads to suppression of c-Fos expression and cell growth inhibition without affecting MAPK activity. In vivo studies confirmed a Dab2 role in regulating c-Fos expression. A possible molecular mechanism of action is that Dab2 limits the entry of the activated MAPK into the nucleus. DAB2 can also interact with Grb2 through its PRD. Receptor tyrosine kinase activation by growth factors increases the binding of DAB2 to Grb2, which interrupts the binding of SOS to Grb2 and leads to suppression of ERK activation.

  • Cell adhesion: DAB2 is an adhesion-responsive phosphoprotein and plays a role in cell adhesion and spreading. Ser24 phosphorylation promotes membrane translocation of DAB2 and its interaction with beta3 integrin. DAB2 negatively regulates integrin alphaIIbbeta3 activation, leading to the inhibition of alphaIIbbeta3-mediated fibrinogen adhesion. In cell experiments during TGFbeta-induced epithelial to mesenchymal trans-differentiation (EMT), Dab2 expression is increased and Dab2 binds to beta1 integrin. In these conditions, Dab2 silencing leads to a decrease in cell adherence, inhibition of EMT, and apoptosis.
  • Angiogenesis: DAB2 can bind to Shc3 domain of Src and this interaction results in Src inactivation. DAB2 is expressed in human umbilical vein endothelial cells (HUVEC). By modulating the activation of Src-FAK signaling and MAPK phosphorylation, DAB2 controls endothelial cell migration and differentiation.
  • Homology The Disabled proteins are a family of adapters involved in cellular signaling, oncogenesis, and development. DAB2 is related to Drosophila Disabled and mammalian Dab1, which regulate neuronal development. DAB2 shares 81% identity with the mouse p96/Dab2 protein.

    Implicated in

    Entity Epithelial ovarian cancer
    Note DAB2 was identified due to the loss of its expression in ovarian cancer cells. Ovarian carcinoma cells transfected with DAB2 showed a reduced growth rate and ability to form tumors in nude mice. Loss of DAB2 expression is not correlated with tumor grade, suggesting that loss of DAB2 expression is an early event in ovarian malignancies and DAB2 behaves as a tumor suppressor.
      
    Entity Prostate cancer
    Note DAB2 is a potent growth inhibitor for prostate cancer cells by suppressing several protein kinase pathways. The PRD of DAB2 is the key functional domain responsible for this activity. It was shown that in prostate cancer cells without endogenous DAB2 expression, a functional motif derived from the PRD of DAB2 conjugated with a delivery system is a potent growth inhibitor.
      
    Entity Breast cancer
    Note DAB2 sensitizes breast cancer cells to cell death upon the loss of cell-matrix attachment by targeting the oncogenic activity of ILK.
      
    Entity Various cancer
    Note Urothelial carcinoma of the bladder, esophageal squamous carcinoma, metastatic pancreatic cancer, colorectal cancer, gestational choriocarcinoma.
    Disease DAB2 expression is down-regulated.
      
    Entity Malignant peripheral nerve sheath tumor, invasive cervical carcinoma
    Note Comparative genomic hybridization (CGH) revealed frequent gains of DAB2.
      

    External links

    Nomenclature
    HGNC (Hugo)DAB2   2662
    Entrez_Gene (NCBI)DAB2  1601  disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)
    Cards
    AtlasDAB2ID40258ch5p13
    GeneCards (Weizmann)DAB2
    Ensembl (Hinxton)ENSG00000153071 [Gene_View]  DAB2 [Vega]
    AceView (NCBI)DAB2
    Genatlas (Paris)DAB2
    euGene (Indiana)1601
    SOURCE (Stanford)NM_001343
    Gene Expression (Array Express) ENSG00000153071
    Genomic and cartography
    GoldenPath (UCSC)DAB2  -  5p13.1   chr5:39407537-39461092 -  5p13   [Description]    (hg18-Mar_2006)
    EnsemblDAB2 - 5p13 [CytoView]
    Mapping of homologs : NCBIDAB2 [Mapview]
    OMIM601236   
    Gene and transcription
    Gene : Genbank (Entrez)AF188298 AK024965 AK130136 AK297984 AK314381
    Reference sequence (RefSeq transcript) :SRSNM_001343
    Reference transcript : EntrezNM_001343
    RefSeq genomic : SRSAC_000048 AC_000137 NC_000005 NT_006576 NW_001838933 NW_922596
    RefSeq genomic : EntrezAC_000048 AC_000137 NC_000005 NT_006576 NW_001838933 NW_922596
    Consensus coding sequences : CCDS NCBIDAB2
    Cluster EST : UnigeneHs.481980 [ SRS ] Hs.481980 [ NCBI ]
    Alternative Splicing : Fast-db (Paris)3145
    Protein : pattern, domain, 3D structure
    Protein : UniProt/SwissProtP98082 (SRS) P98082 (Expasy) P98082 (Uniprot)
    With graphics : InterProP98082
    Splice isoforms : VarSplice FASTAP98082(VarSplice FASTA)
    Domaine pattern : Prosite (SRS)PID (PS01179)   
    Domain pattern : Prosite (Expaxy)PID (PS01179)   
    Domains : Interpro (SRS)PH_type    PTyr_interaction_dom   
    Domains : Interpro (EBI)PH_type    PTyr_interaction_dom   
    Related proteins : CluSTrP98082
    Domain families : Pfam SRSPID (PF00640)   
    Domain families : Pfam SangerPID (PF00640)   
    Domain families : Pfam NCBIpfam00640   
    Domain families : Smart EMBLPTB (SM00462)  
    Blocks (Seattle)P98082
    Crystal structure of protein : PDB SRS
    Crystal structure of protein : PDBSum
    Crystal structure of protein : IMB
    Crystal structure of protein : PDB RSDB
    HPRD03139
    Protein Interaction databases
    DIP (DOE-UCLA)P98082
    IntAct (EBI)P98082
    Polymorphism : SNP, mutations, diseases
    Single Nucleotide Polymorphism (SNP) : dbSNP NCBIDAB2
    SNP : GeneSNP UtahDAB2
    SNP : HGBaseDAB2
    Genetic variants : HAPMAPDAB2
    Somatic Mutations in Cancer : COSMICDAB2 
    Mutations and Diseases : HGMDDAB2
    Hereditary diseases : OMIM601236   
    Hereditary diseases : GENETests601236   
    Diseases : Genetic AssociationDAB2
    General knowledge
    Homologs : HomoloGeneDAB2
    Homology/Alignments : Family Browser UCSCDAB2
    Phylogenetic Trees/Animal Genes : TreeFamDAB2
    Chemical/Protein Interactions : CTD1601
    Keywords Ontology : AmiGOcell morphogenesis involved in differentiation  in utero embryonic development  coated pit  receptor-mediated endocytosis  pinocytosis  excretion  protein C-terminus binding  cell proliferation  membrane  negative regulation of cell growth  clathrin coated vesicle membrane  cytoplasmic vesicle  
    Keywords Ontology : EGO-EBIcell morphogenesis involved in differentiation  in utero embryonic development  coated pit  receptor-mediated endocytosis  pinocytosis  excretion  protein C-terminus binding  cell proliferation  membrane  negative regulation of cell growth  clathrin coated vesicle membrane  cytoplasmic vesicle  
    Pathways : BIOCARTAAlternative Complement Pathway [Genes]    Classical Complement Pathway [Genes]    Complement Pathway [Genes]    Lectin Induced Complement Pathway [Genes]   
    Pathways : KEGG
    Other databases
    Probes
    Probes : ImagenesDAB2 Related clones (RZPD - Berlin)
    Literature
    PubMed48 Pubmed reference(s) in Entrez
    PubGeneDAB2

    Bibliography

    Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product.
    Xu XX, Yang W, Jackowski S, Rock CO.
    J Biol Chem. 1995 Jun 9;270(23):14184-91.
    PMID 7775479
     
    Sequence, genomic structure, and chromosomal assignment of human DOC-2.
    Albertsen HM, Smith SA, Melis R, Williams B, Holik P, Stevens J, White R.
    Genomics. 1996 Apr 15;33(2):207-13.
    PMID 8660969
     
    DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer.
    Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS.
    Oncogene. 1998 May 7;16(18):2381-7.
    PMID 9620555
     
    Disabled-2 inactivation is an early step in ovarian tumorigenicity.
    Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX.
    Oncogene. 1999 May 20;18(20):3104-13.
    PMID 10340382
     
    The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer.
    Tseng CP, Ely BD, Pong RC, Wang Z, Zhou J, Hsieh JT.
    J Biol Chem. 1999 Nov 5;274(45):31981-6.
    PMID 10542228
     
    Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2).
    Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, Smith ER, Dong FB, Xu XX.
    Genomics. 2000 Dec 15;70(3):381-6.
    PMID 11161789
     
    Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation.
    He J, Smith ER, Xu XX.
    J Biol Chem. 2001 Jul 20;276(29):26814-8. Epub 2001 May 18.
    PMID 11359772
     
    The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway.
    Hocevar BA, Smine A, Xu XX, Howe PH.
    EMBO J. 2001 Jun 1;20(11):2789-801.
    PMID 11387212
     
    Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2.
    Morris SM, Cooper JA.
    Traffic. 2001 Feb;2(2):111-23.
    PMID 11247302
     
    Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells.
    Smith ER, Capo-chichi CD, He J, Smedberg JL, Yang DH, Prowse AH, Godwin AK, Hamilton TC, Xu XX.
    J Biol Chem. 2001 Dec 14;276(50):47303-10. Epub 2001 Sep 27.
    PMID 11577091
     
    DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway.
    Wang SC, Makino K, Xia W, Kim JS, Im SA, Peng H, Mok SC, Singletary SE, Hung MC.
    Oncogene. 2001 Oct 18;20(47):6960-4.
    PMID 11687976
     
    The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2.
    Zhou J, Hsieh JT.
    J Biol Chem. 2001 Jul 27;276(30):27793-8. Epub 2001 May 22.
    PMID 11371563
     
    Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor.
    Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, Watkins SC, Traub LM.
    EMBO J. 2002 Sep 16;21(18):4915-26.
    PMID 12234931
     
    Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion.
    Rosenbauer F, Kallies A, Scheller M, Knobeloch KP, Rock CO, Schwieger M, Stocking C, Horak I.
    EMBO J. 2002 Feb 1;21(3):211-20.
    PMID 11823414
     
    Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis.
    Yang DH, Smith ER, Roland IH, Sheng Z, He J, Martin WD, Hamilton TC, Lambeth JD, Xu XX.
    Dev Biol. 2002 Nov 1;251(1):27-44.
    PMID 12413896
     
    Cell cycle-dependent phosphorylation of Disabled-2 by cdc2.
    He J, Xu J, Xu XX, Hall RA.
    Oncogene. 2003 Jul 17;22(29):4524-30.
    PMID 12881709
     
    Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer.
    Zhou J, Scholes J, Hsieh JT.
    J Biol Chem. 2003 Feb 28;278(9):6936-41. Epub 2002 Dec 8.
    PMID 12473651
     
    Disabled-2 is a negative regulator of integrin alpha(IIb)beta(3)-mediated fibrinogen adhesion and cell signaling.
    Huang CL, Cheng JC, Liao CH, Stern A, Hsieh JT, Wang CH, Hsu HL, Tseng CP.
    J Biol Chem. 2004 Oct 1;279(40):42279-89. Epub 2004 Jul 26.
    PMID 15280374
     
    Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma.
    Hidalgo A, Baudis M, Petersen I, Arreola H, Pina P, Vazquez-Ortiz G, Hernandez D, Gonzalez J, Lazos M, Lopez R, Perez C, Garcia J, Vazquez K, Alatorre B, Salcedo M.
    BMC Cancer. 2005 Jul 9;5:77.
    PMID 16004614
     
    Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT).
    Prunier C, Howe PH.
    J Biol Chem. 2005 Apr 29;280(17):17540-8. Epub 2005 Feb 25.
    PMID 15734730
     
    The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer.
    Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT.
    Cancer Res. 2005 Nov 1;65(21):9906-13.
    PMID 16267015
     
    Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization.
    Nakagawa Y, Yoshida A, Numoto K, Kunisada T, Wai D, Ohata N, Takeda K, Kawai A, Ozaki T.
    Oncol Rep. 2006 Feb;15(2):297-303.
    PMID 16391845
     
    Inhibition of mitogen-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle.
    Zhou J, Fan J, Hsieh JT.
    Cancer Res. 2006 Sep 15;66(18):8954-8.
    PMID 16982733
     
    Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT.
    Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4400-6.
    PMID 17671122
     
    Myosin VI targeting to clathrin-coated structures and dimerization is mediated by binding to Disabled-2 and PtdIns(4,5)P2.
    Spudich G, Chibalina MV, Au JS, Arden SD, Buss F, Kendrick-Jones J.
    Nat Cell Biol. 2007 Feb;9(2):176-83. Epub 2006 Dec 24.
    PMID 17187061
     
    Disabled-2 is an epithelial surface positioning gene.
    Yang DH, Cai KQ, Roland IH, Smith ER, Xu XX.
    J Biol Chem. 2007 Apr 27;282(17):13114-22. Epub 2007 Mar 5.
    PMID 17339320
     
    The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin.
    Jiang Y, Prunier C, Howe PH.
    Oncogene. 2008 Mar 20;27(13):1865-75. Epub 2007 Oct 8.
    PMID 17922036
     
    Morphogenesis of human endothelial cells is inhibited by DAB2 via Src.
    Orlandini M, Nucciotti S, Galvagni F, Bardelli M, Rocchigiani M, Petraglia F, Oliviero S.
    FEBS Lett. 2008 Jul 23;582(17):2542-8. Epub 2008 Jun 26.
    PMID 18582465
     
    C-Fos elimination compensates for disabled-2 requirement in mouse extraembryonic endoderm development.
    Yang DH, Smith ER, Cai KQ, Xu XX.
    Dev Dyn. 2009 Mar;238(3):514-23.
    PMID 19191218
     
    REVIEW articlesautomatic search in PubMed
    Last year publicationsautomatic search in PubMed

    Search in all EBI   NCBI

    Contributor(s)

    Written05-2009Maurizio Orlandini
    Department of Molecular Biology, Via Fiorentina 1, 53100 - Siena, Italy

    Citation

    This paper should be referenced as such :
    Orlandini M . DAB2 (disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)). Atlas Genet Cytogenet Oncol Haematol. May 2009 .
    URL : http://AtlasGeneticsOncology.org/Genes/DAB2ID40258ch5p13.html

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Sat Feb 27 10:48:02 CET 2010

    Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.